Rigavidone, 0.15 mg+0.03 mg 63 pcs

Pharmacodynamics

Rigevidone is an oral monophasic combined estrogen-gestagen contraceptive.
When taken orally, it inhibits pituitary gonadotropic hormone secretion.

The contraceptive effect is associated with several mechanisms. As a gestagenic component (progestin) contains a derivative of 19-nortestosterone – levonorgestrel, which is superior in activity to the corpus luteum hormone progesterone (and the synthetic analog of the latter – pregnin), acts at the level of receptors without prior metabolic conversions.

The estrogenic component is ethinyl estradiol. Under the influence of levonorgestrel there is a blockade of release of releasing releasing hormones (LH and FSH) of hypothalamus, inhibition of secretion of gonadotropic hormones by pituitary, which leads to inhibition of maturation and exit of the egg ready for fertilization (ovulation). Contraceptive effect is enhanced by ethinyl estradiol. Maintains high viscosity of cervical mucus (makes it difficult for sperm to enter the uterine cavity). In addition to the contraceptive effect of regular use normalizes the menstrual cycle and contributes to the prevention of a number of gynecological diseases, including the tumor nature.

Pharmacokinetics

Levonorgestrel is quickly absorbed (less than 4 hours). Levonorgestrel has no effect of first passage through the liver. When levonorgestrel is coadministered with ethinylestradiol, there is a dose-response relationship with maximum plasma concentration. TCmax (time of reaching maximum concentration) of levonorgestrel is 2 hours, T1/2 (elimination half-life) is 8-30 hours (average 16 hours). (on average 16 hours). Most of the levonorgestrel is bound in the blood with albumin and hGH (sex hormone-binding globulin).

Ethinylestradiol is quickly and almost completely absorbed from the intestine. Ethinylestradiol has an inherent effect of primary passage through the liver, TCmax is 1.5 hours, and the elimination half-life is about 26 hours.

When administered orally, ethinylestradiol is excreted from the blood plasma within 12 hours, the elimination half-life is 5.8 hours.
Metabolism of ethinylestradiol is performed in the liver and intestine. Metabolites of ethinylestradiol are water-soluble products of sulfate or glucuronide conjugation and enter the intestine with bile, where they are disintegrated by intestinal bacteria.

The two components (levonorgestrel and ethinylestradiol) are excreted with breast milk. The active substances are metabolized in the liver, the T1/2 is 2-7 hours.

Levonorgestrel is excreted by the kidneys (60%) and through the intestine (40%); ethinylestradiol by the kidneys (40%) and through the intestine (60%).

Indications

Oral contraception, functional menstrual disorders (including dysmenorrhea without an organic cause, dysfunctional metrorrhagia, premenstrual syndrome).

Active ingredient

Composition

Active substances:

ethinyl estradiol: 0.03 mg,

levonorgestrel; 0.15 mg

Excipients:

in the core of the tablet:

colloidal silicon dioxide,

magnesium stearate,

talc,

corn starch,

lactose monohydrate;

in the tablet shell:

sucrose,

talc,

calcium carbonate,

titanium dioxide,

copovidone,

How to take, the dosage

To be taken orally, without chewing and with a small amount of liquid.

If hormonal contraception was not used during the previous menstrual cycle, Rigevidone is used from the first day of the period, taking 1 tablet daily for 21 days at the same time of the day.

There follows a 7-day break, during which menstrual bleeding occurs. The next 21-day pill cycle of the new 21-pill package must begin the day after the 7-day break, i.e. on the eighth day, even if bleeding has not stopped. In this way, the beginning of each new package of medication falls on the same day of the week.

If you switch to taking Rigevidone from another oral contraceptive, a similar regimen is used. Take the medication for as long as contraception is still needed.

After an abortion, it is recommended that the drug be started on the day of the abortion or the day after surgery.

After delivery, the drug can only be prescribed to women who are not breastfeeding; the contraceptive should not be taken until the first day of menstruation. The use of the drug is contraindicated during lactation.

Missed pills; a missed pill should be taken within the next 12 hours. If 36 hours have passed since the last pill was taken, contraception is unreliable. To avoid intermenstrual bleeding, you should continue taking the product from the already started package, except for the missed pill(s). If the pills are missed, we recommend another, non-hormonal method of contraception (e.g., barrier contraception).

For therapeutic purposes; the dose of Rigevidone and the route of administration are selected by the physician on a case-by-case basis.

Interaction

Barbiturates, some antiepileptic drugs (carbamazepine, phenytoin), sulfonamides, pyrazolone derivatives can increase the metabolism of the steroid hormones included in the drug.

Lack of contraceptive effectiveness may also be observed when concomitantly prescribed with some antimicrobials (including ampicillin, rifampicin, chloramphenicol, neomycin, polymyxin B, sulfonamides, tetracyclines), which is associated with changes in the intestinal microflora.

In concomitant use with anticoagulants, coumarin or indandion derivatives, additional determination of the prothrombin index and change of the anticoagulant dose may be required.

The use of tricyclic antidepressants, maprotiline, beta-adrenoblockers may increase their bioavailability and toxicity.

When using oral hypoglycemic agents and insulin, it may be necessary to change their dosage.

When combined with bromocriptine its effectiveness decreases.

When combined with drugs with potential hepatotoxic effects, such as the drug dantrolene, an increase in hepatotoxicity is observed, especially in women over 35 years.

Rigevidone should be used with caution in combination with the drugs listed above.

Special Instructions

Before starting hormonal contraception and every 6 months thereafter, a general medical and gynecological examination is recommended, including cervical smear cytology, assessment of mammary glands, determination of blood glucose, cholesterol and other liver function parameters, BP control, urine analysis).

Prescribing Rigevidone to women with thromboembolic diseases at a young age and a family history of increased blood clotting is not recommended.

The use of oral contraception is allowed no earlier than 6 months after having had viral hepatitis on condition of normalization of liver functions.

In case of severe upper abdominal pain, hepatomegaly, and signs of intra-abdominal bleeding, liver tumor may be suspected. If necessary, the drug should be discontinued.

In case of impaired liver function while taking Rigevidone, a consultation with a general practitioner is necessary.

If acyclic (intermenstrual) bleeding occurs, the use of Rigevidone should be continued, as most of these bleeding stops spontaneously. If acyclical (intermenstrual) bleeding persists or recurs, a medical exam should be performed to rule out an organic reproductive system disorder.

If vomiting or diarrhea occurs, the drug should be continued with another, non-hormonal method of contraception.

Women who smoke and take hormonal contraceptives have an increased risk of cardiovascular disease with serious consequences (myocardial infarction, stroke). The risk increases with age and according to the number of cigarettes smoked (especially in women over the age of 35).

The drug should be discontinued in the following cases:

– If a migraine-like headache occurs for the first time or worsens.
– If an unusually severe headache occurs.
– If there are early signs of phlebitis or phlebothrombosis (unusual pain or swollen veins in the legs).
– In the occurrence of jaundice or hepatitis without jaundice.
– In cerebrovascular disorders.
– In the occurrence of stabbing pain of unclear etiology when breathing or coughing, pain and feeling of tightness in the chest.
– In acute deterioration of visual acuity.
– In suspected thrombosis or heart attack.
– In sudden increase in BP.
– In the occurrence of generalized itching.
– In the frequency of epileptic seizures.
– In 3 months before the planned pregnancy.
– Approximately 6 weeks before the planned surgical intervention.
– In case of prolonged immobilization.
– In case of a pregnancy.

– Application in liver function disorders: application is contraindicated in severe liver diseases (including congenital hyperbilirubinemia – Gilbert, Dubin-Johnson and Rotor syndromes; liver tumors).

– Administration in renal dysfunction: Caution is required if it is necessary to prescribe the drug in patients with renal dysfunction.

Impact on ability to drive vehicles and operate machinery: Administration of the drug does not affect the ability to drive vehicles and operate other mechanisms with increased risk of injury.

Contraindications

– Severe liver diseases (including congenital hyperbilirubinemia – Gilbert, Dubin-Johnson and Rotor syndromes).
– Cholecystitis.
– Presence or history of severe cardiovascular and cerebrovascular diseases.
– Thromboembolism and predisposition to it.
– Malignant tumors (especially breast or endometrial cancer).
– Liver tumors.
– Familial forms of hyperlipidemia.
– Severe forms of arterial hypertension.
– Sickle-cell anemia.
– Chronic hemolytic anemia.
– Vaginal bleeding of unknown etiology.
– Bubble drift.
– Migraine.
– Otosclerosis.
– A history of idiopathic jaundice in pregnant women.
– Severe skin itching in pregnant women.
– Pregnant herpes.
– Age over 40 years.
– Pregnancy.
– Lactation period (breastfeeding).
– Hypersensitivity to the components of the drug.

The drug should be used with caution:

– Diseases of the liver and gallbladder.
– Epilepsy.
– Depression.
– Ulcerative colitis.
– Uterine myoma.
– Mastopathy.
– Tuberculosis.
– Kidney diseases.
– Diabetes.
– Cardiovascular diseases.
– Arterial hypertension.
– Kidney function disorders.
– Varicose veins.
– Phlebitis.
– Multiple sclerosis.
– Minor chorea.
– In adolescence (without regular ovulatory cycles).

Side effects

The drug is usually well tolerated.

Possible transient, spontaneous side effects include: nausea, vomiting, headache, breast engorgement, weight and libido changes, mood changes, acyclic bloody discharge, and, in some cases, eyelid edema, conjunctivitis, visual disturbances, discomfort while wearing contact lenses (these phenomena are temporary and disappear after withdrawal without any therapy).

Long-term use may very rarely cause chloasma, hearing loss, generalized pruritus, jaundice, calf cramps, increased frequency of epileptic seizures. Hypertriglyceridemia, hyperglycemia, decreased glucose tolerance, increased arterial pressure (BP), thrombosis and venous thromboembolism, jaundice, skin rash, change of vaginal secretion pattern, vaginal candidiasis, increased fatigue, diarrhea are rarely observed.

Overdose

There are no known cases of toxic effects due to overdose.

Pregnancy use

The drug is contraindicated in pregnancy and during lactation (breastfeeding).

Similarities